Kendra Adams - 13 Feb 2025 Form 4 Insider Report for C4 Therapeutics, Inc. (CCCC)

Role: Chief Financial Officer
Signature: /s/ Shagha Russell, Attorney-in-Fact
Issuer symbol: CCCC
Transactions as of: 13 Feb 2025
Net transactions value: -$20,459
Form type: 4
Filing time: 18 Feb 2025, 16:54:48 UTC
Previous filing: 12 Nov 2024
Next filing: 19 Sep 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CCCC	Common Stock	Tax liability	$5,962	-1,863	-2.2%	$3.20	82,576	13 Feb 2025	Direct	F1
transaction	CCCC	Common Stock	Award	$0	+87,100	+105%	$0.000000	169,676	14 Feb 2025	Direct	F2
transaction	CCCC	Common Stock	Tax liability	$14,498	-4,559	-2.7%	$3.18	165,117	14 Feb 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CCCC	Stock Option (Right to Buy)	Award	$0	+130,600		$0.000000	130,600	14 Feb 2025	Common Stock	130,600	$3.18	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") and does not represent a sale by the Reporting Person.
F2	Represents RSUs. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following the grant date, with the first installment vesting on February 14, 2026.
F3	The shares underlying this option shall vest and become exercisable in forty-eight equal monthly installments following the grant date, with the first installment vesting on March 14, 2025.